Disease · MONDO_0019954
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 16 of 16
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Everolimus vs STZ - 5FU: deaths from any cause | 26 of 105 | 35 of 104 | 209 | NCT02246127 | Trial comparisons |
| Everolimus vs STZ - 5FU: serious adverse events | 28 of 105 | 26 of 104 | 209 | NCT02246127 | Trial comparisons |
| Sunitinib vs Placebo: serious adverse events | 22 of 83 | 34 of 82 | 165 | NCT00428597 | Trial comparisons |
| Stratum 1: Everolimus 10 mg vs Stratum 2: Everolimus 10 mg + Octreotide Depot: serious adverse events | 63 of 115 | 27 of 45 | 160 | NCT00363051 | Trial comparisons |
| Everolimus LAR + Pasireotide vs Everolimus: serious adverse events | 41 of 78 | 49 of 81 | 159 | NCT01374451 | Trial comparisons |
| Arm I (Octreotide Acetate and Everolimus) vs Arm II (Octreotide Acetate, Everolimus, and Bevacizumab): serious adverse events | 20 of 74 | 31 of 73 | 147 | NCT01229943 | Trial comparisons |
| Arm A (Temozolomide) vs Arm B (Temozolomide and Capecitabine): deaths from any cause | 42 of 72 | 33 of 72 | 144 | NCT01824875 | Trial comparisons |
| Arm A (Temozolomide) vs Arm B (Temozolomide and Capecitabine): serious adverse events | 15 of 68 | 32 of 71 | 139 | NCT01824875 | Trial comparisons |
| Targeted Therapy at Inclusion vs Other Treatments at Inclusion: Number of Participants Who Had a Change in Their Treatment - Based on Targeted Therapy Group and Other Treatments Group at Inclusion | 44 of 55 | 68 of 79 | 134 | NCT02264665 | Trial comparisons |
| Neuroendocrine Tumors of the Pancreas vs Neuroendocrine Tumors of Gastrointestinal Tract: deaths from any cause | 21 of 55 | 29 of 56 | 111 | NCT02678780 | Trial comparisons |
| Neuroendocrine Tumors of the Pancreas vs Neuroendocrine Tumors of Gastrointestinal Tract: serious adverse events | 23 of 55 | 24 of 56 | 111 | NCT02678780 | Trial comparisons |
| BEZ235 vs Everolimus: serious adverse events | 11 of 31 | 9 of 31 | 62 | NCT01628913 | Trial comparisons |
| Metastatic or Unresectable PNET vs Metastatic or Unresectable Carcinoid: Objective Response Rate (ORR) | 3 of 20 | 7 of 41 | 61 | NCT01466036 | Trial comparisons |
| Metastatic or Unresectable PNET vs Metastatic or Unresectable Carcinoid: deaths from any cause | 1 of 20 | 3 of 41 | 61 | NCT01466036 | Trial comparisons |
| Metastatic or Unresectable PNET vs Metastatic or Unresectable Carcinoid: serious adverse events | 15 of 20 | 24 of 41 | 61 | NCT01466036 | Trial comparisons |
| BEZ235 300 mg Bid vs BEZ235 400 mg Bid: serious adverse events | 8 of 20 | 5 of 11 | 31 | NCT01658436 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019954/comparisons